EBNEO Commentary: Precision management of the patent ductus arteriosus in micropreemies

Affiliations

Comment

Souvik Mitra. Acta Paediatr. 2023 Sep.

. 2023 Sep;112(9):2018-2019.

doi: 10.1111/apa.16853. Epub 2023 May 28.

¹ Department of Pediatrics, Department of Community Health & Epidemiology, Dalhousie University & IWK Health, Halifax, Canada.

No abstract available

Comment on

Impact of early screening echocardiography and targeted PDA treatment on neonatal outcomes in "22-23" week and "24-26" infants.
Giesinger RE, Hobson AA, Bischoff AR, Klein JM, McNamara PJ. Giesinger RE, et al. Semin Perinatol. 2023 Mar;47(2):151721. doi: 10.1016/j.semperi.2023.151721. Epub 2023 Mar 5. Semin Perinatol. 2023. PMID: 36882362

1. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol. 2010;30(4):241-252.
1. Mitra S, de Boode WP, Weisz DE, Shah PS. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023;4(4):CD013588.
1. de Freitas Martins F, Ibarra Rios D, Resende MHF, et al. Relationship of patent ductus arteriosus size to echocardiographic markers of shunt volume. J Pediatr. 2018;202:50-55.e3.
1. Zonnenberg I, de Waal K. The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr. 2012;101(3):247-251.
1. Liebowitz M, Katheria A, Sauberan J, et al. Lack of equipoise in the PDA-TOLERATE trial: a comparison of eligible infants enrolled in the trial and those treated outside the trial. J Pediatr. 2019;213:222-226.e2.